Peroxisome proliferator-activated receptor-gamma agonists and diabetes: current evidence and future perspectives.
Since their initial availability in 1997, the thiazolidinediones (TZDs) have become one of the most commonly prescribed classes of medications for type 2 diabetes. In addition to glucose control, the TZDs have a number of pleiotropic effects on myriad traditional and non-traditional risk factors for diabetes. TZDs may benefit cardiovascular parameters, such as lipids, blood pressure, inflammatory biomarkers, endothelial function and fibrinolytic state. In this review, we summarise the experimental, preclinical and clinical data regarding the effects of the TZDs in conditions for which they are indicated and discuss their potential in the treatment of other conditions.
Chiarelli
Francesco
F
Department of Pediatrics, University of Chieti, Italy.
Di Marzio
Daniele
D
D017667:Adipocytes / Q000187:drug effects / Q000378:metabolism; D000818:Animals; D050197:Atherosclerosis / Q000188:drug therapy / Q000378:metabolism; D001794:Blood Pressure / Q000187:drug effects; D003924:Diabetes Mellitus, Type 2 / Q000188:drug therapy* / Q000378:metabolism / Q000503:physiopathology; D004730:Endothelium, Vascular / Q000187:drug effects / Q000503:physiopathology; D006801:Humans; D007004:Hypoglycemic Agents / Q000009:adverse effects / Q000627:therapeutic use*; D007249:Inflammation / Q000188:drug therapy / Q000378:metabolism; D007333:Insulin Resistance; D008055:Lipids / Q000097:blood; D047495:PPAR gamma / Q000819:agonists* / Q000378:metabolism; D045162:Thiazolidinediones / Q000009:adverse effects / Q000627:therapeutic use*; D016896:Treatment Outcome
D007004:Hypoglycemic Agents; D008055:Lipids; D047495:PPAR gamma; D045162:Thiazolidinediones